Meme kanseri tedavisi için mezogözenekli silika nanopartiküller içinde doksorubisin kapsüllenmesi ve kontrollü salınımı
Yükleniyor...
Dosyalar
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Selçuk Üniversitesi, Fen Bilimleri Enstitüsü
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Meme kanseri şu anda en yaygın kanser türlerinden biridir ve yaklaşık olarak 10 kadından biri hayatlarının bir döneminde meme kanseri geliştirecektir. Kadınlarda ikinci en yaygın kanser ölüm nedenidir ve radikal mastektomiye rağmen etkilenen kadınların yaklaşık üçte biri ölmektedir. Meme kanseri için temel tedavi yöntemi kemoterapidir. Fakat sağlıklı hücrelere verdiği zararlar dolayısıyla vücut direncini düşürerek kötü sonuçlar doğurabilmektedir. Mezogözenekli silika nanoparçacıkları (MSNP'ler), ilaç dağıtımı için benzersiz özelliklere sahip potansiyel nano taşıyıcılar arasındadır. Son zamanlarda yapılan araştırmalar, mezogözenekli silika nanoparçacıklarının (MSNP'ler) ilaç dağıtım uygulamalarında en umut verici nano taşıyıcılardan biri olduğunu göstermektedir. Ayarlanabilir ve geniş hacimli gözenekler ve geniş yüzey alanı gibi yapısal özellikleri, artan ilaç yükleme kapasitesi nedeniyle onları ilaç dağıtımı için çekici nanotaşıyıcılar haline getirir. Bu çalışmada, mezogözenekli nanopartiküllerin L929 sağlıklı fare fibroblastik hücrelerine, MCF-7 meme kanser hücrelerine, ve HUVEC sağlıklı insan hücrelerine karşı toksisitesi in vitro ortamda test edildi. MSNP'lerin sentezi literatürde verilen yönteme göre yapıldı. Sentezlenen nanopartiküllerin yapısı TEM ve FT-IR ile karakterize edildi. MCF-7 hücrelerinin kültür ortamı olarak %10 fetal dana serumu (fetal bovine serum, FBS), gentamisin içeren RPMI-1640 besiyeri kullanıldı. HUVEC ve L929 hücrelerinin kültür ortamı olarak % 10 fetal dana serumu (fetal bovine serum, FBS), penisilin içeren DMEM high glucose besiyeri kullanıldı. MCF-7, L929 ve HUVEC hücreleri uygun miktarlarda DMSO ile çözülen 7,81-1000 µg/mL'lik konsantrasyonlarda MSN stok çözeltisi ilave edildi. Kontrol grubu her deneyde %0,6 konsantrasyonda DMSO ile muhafaza edildi. Hücrelerin 24,48 ve 72 saatte MSN' ye karşı olan sitotoksisiteleri incelendi. Mezogözenekli silika nanopartiküle 5/1 oranında doksorubisin yüklendi. Daha sonra MCF-7 ve HUVEC hücreleri üzerinde 24,48 ve 72 saatte MSN-Dox' a karşı olan sitotoksisiteleri incelendi. Araştırmamızda, MSNP'nin 7,81-125 µg/mL konsantrasyon aralığında MCF-7, L929 ve HUVEC hücrelerinde sitotoksisite göstermediği görülmüştür. Ayrıca, MTT sitotoksisite analizi, MSNP'lerin serbest DOX'a kıyasla düşük toksisite sergilediğini ortaya çıkarmıştır. Sentezlenen MSNP'lerin belirlenen dozlarda ilaç taşıyıcı sistem olarak kullanılabileceği söylenebilir.
Breast cancer is currently one of the most common types of cancer, and approximately one in 10 women will develop breast cancer at some point in their lives. It is the second most common cause of cancer death in women, and about a third of affected women die despite radical mastectomy. The main treatment for breast cancer is chemotherapy. However, due to the damage it causes to healthy cells, it can cause bad results by lowering the body's resistance. Mesoporous silica nanoparticles (MSNPs) are among the potential nanocarriers with unique properties for drug delivery. Recent research shows that mesoporous silica nanoparticles (MSNPs) are one of the most promising nanocarriers in drug delivery applications. Their structural features such as tunable and large volume pores and large surface area make them attractive nanocarriers for drug delivery due to their increased drug loading capacity. In this study, the toxicity of mesoporous nanoparticles against L929 healthy mouse fibroblastic cells, MCF-7 breast cancer cells and HUVEC healthy human cells was tested in vitro. The synthesis of MSNPs were done according to the method given in the literature. The structure of the synthesized nanoparticles was characterized by TEM and FT-IR. As the culture medium of MCF-7 cells, 10% fetal calf serum (fetal bovine serum, FBS) and RPMI-1640 medium containing gentamicin were used. As the culture medium of HUVEC and L929 cells, 10% fetal calf serum (fetal bovine serum, FBS), DMEM high glucose medium containing penicillin was used. MCF-7, L929 and HUVEC cells were added to MSN stock solution at concentrations of 7.81-1000 µg/mL dissolved with appropriate amounts of DMSO. The control group was maintained with DMSO at a concentration of 0.6% in each experiment. The cytotoxicity of the cells against MSN at 24, 48 and 72 hours was examined. Doxorubicin was loaded into the mesoporous silica nanoparticle at a ratio of 5/1. Then, their cytotoxicity against MSN-Dox was examined on MCF-7 and HUVEC cells at 24, 48 and 72 hours. In our study, it was observed that MSN did not show cytotoxicity in MCF-7, L929 and HUVEC cells in the concentration range of 7.81-125 µg/mL. Furthermore, MTT cytotoxicity analysis revealed that MSNPs exhibited low toxicity compared to free DOX. It can be said that the synthesized MSNPs can be used as drug carrier systems at determined doses.
Breast cancer is currently one of the most common types of cancer, and approximately one in 10 women will develop breast cancer at some point in their lives. It is the second most common cause of cancer death in women, and about a third of affected women die despite radical mastectomy. The main treatment for breast cancer is chemotherapy. However, due to the damage it causes to healthy cells, it can cause bad results by lowering the body's resistance. Mesoporous silica nanoparticles (MSNPs) are among the potential nanocarriers with unique properties for drug delivery. Recent research shows that mesoporous silica nanoparticles (MSNPs) are one of the most promising nanocarriers in drug delivery applications. Their structural features such as tunable and large volume pores and large surface area make them attractive nanocarriers for drug delivery due to their increased drug loading capacity. In this study, the toxicity of mesoporous nanoparticles against L929 healthy mouse fibroblastic cells, MCF-7 breast cancer cells and HUVEC healthy human cells was tested in vitro. The synthesis of MSNPs were done according to the method given in the literature. The structure of the synthesized nanoparticles was characterized by TEM and FT-IR. As the culture medium of MCF-7 cells, 10% fetal calf serum (fetal bovine serum, FBS) and RPMI-1640 medium containing gentamicin were used. As the culture medium of HUVEC and L929 cells, 10% fetal calf serum (fetal bovine serum, FBS), DMEM high glucose medium containing penicillin was used. MCF-7, L929 and HUVEC cells were added to MSN stock solution at concentrations of 7.81-1000 µg/mL dissolved with appropriate amounts of DMSO. The control group was maintained with DMSO at a concentration of 0.6% in each experiment. The cytotoxicity of the cells against MSN at 24, 48 and 72 hours was examined. Doxorubicin was loaded into the mesoporous silica nanoparticle at a ratio of 5/1. Then, their cytotoxicity against MSN-Dox was examined on MCF-7 and HUVEC cells at 24, 48 and 72 hours. In our study, it was observed that MSN did not show cytotoxicity in MCF-7, L929 and HUVEC cells in the concentration range of 7.81-125 µg/mL. Furthermore, MTT cytotoxicity analysis revealed that MSNPs exhibited low toxicity compared to free DOX. It can be said that the synthesized MSNPs can be used as drug carrier systems at determined doses.
Açıklama
Anahtar Kelimeler
HUVEC, Kanser, L929, MCF-7, Mezogözenekli Silika, Nanopartikül, Cancer, Drug Release, Mesoporous Silica, Nanoparticle
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Karataş, Ş. D. (2023). Meme kanseri tedavisi için mezogözenekli silika nanopartiküller içinde doksorubisin kapsüllenmesi ve kontrollü salınımı. (Yüksek Lisans Tezi). Selçuk Üniversitesi, Fen Bilimleri Enstitüsü, Konya.
